MCID: OLF005
MIFTS: 52

Olfactory Neuroblastoma

Categories: Cancer diseases, Neuronal diseases, Rare diseases, Smell/Taste diseases

Aliases & Classifications for Olfactory Neuroblastoma

MalaCards integrated aliases for Olfactory Neuroblastoma:

Name: Olfactory Neuroblastoma 12 54 60 15 17 74
Esthesioneuroblastoma 12 77 54 60 56
Paranasal Sinus Olfactory Neuroblastoma 12
Esthesioneuroblastoma, Olfactory 45
Olfactory Esthesioneuroblastoma 12
Esthesioneuroepithelioma 12
Asthesioneuroblastoma 12

Characteristics:

Orphanet epidemiological data:

60
esthesioneuroblastoma
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: Adult,Elderly;

Classifications:

Orphanet: 60  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:369
MeSH 45 D018304
NCIt 51 C3789 C6016
SNOMED-CT 69 68614005 76060004
ICD10 via Orphanet 35 C30.0
UMLS via Orphanet 75 C0206717
Orphanet 60 ORPHA1957
UMLS 74 C0206717

Summaries for Olfactory Neuroblastoma

NIH Rare Diseases : 54 Olfactory neuroblastoma is a rare cancer of the upper part of the nasal cavity called the cribiform plate, which is a bone deep in the skull between the eyes, and above the ethmoid sinuses. It accounts for about 5% of all cancers of the nasal cavity and paranasal sinuses. It develops in nerve tissue associated with the sense of smell (olfactory nerve). It can occur at any age, but typically is found in adulthood. Symptoms may be nonspecific and include a blockage of the nasal passageways due to the tumor, facial pain, runny nose, and nosebleeds. Treatment usually includes surgery to remove the tumor, radiation therapy, and sometimes chemotherapy.

MalaCards based summary : Olfactory Neuroblastoma, also known as esthesioneuroblastoma, is related to spinal meningioma and cystadenoma. An important gene associated with Olfactory Neuroblastoma is SYP (Synaptophysin), and among its related pathways/superpathways are Apoptosis Pathway and Transcriptional misregulation in cancer. The drugs Fentanyl and Fluconazole have been mentioned in the context of this disorder. Affiliated tissues include bone, brain and eye, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 77 Esthesioneuroblastoma, also called "olfactory neuroblastoma", is a rare cancer of the nasal cavity.... more...

Related Diseases for Olfactory Neuroblastoma

Diseases related to Olfactory Neuroblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 239)
# Related Disease Score Top Affiliating Genes
1 spinal meningioma 30.8 CHGA ENO2
2 cystadenoma 30.7 CHGA SYP
3 sinonasal undifferentiated carcinoma 30.7 ENO2 SYP
4 olfactory groove meningioma 30.3 CHGA SYP
5 meningioma, familial 30.3 ENO2 SSTR2 SYP
6 central neurocytoma 30.1 CHGA ENO2 SYP
7 paraganglioma 30.0 CHGA ENO2 SYP
8 small cell cancer of the lung 29.7 CHGA ENO2 SSTR2 SYP
9 ganglioneuroma 29.4 CHGA ENO2 NTRK1 NTRK2 SYP
10 ewing sarcoma 28.8 CHGA ENO2 EWSR1 PTPRC S100B SYP
11 nasal cavity olfactory neuroblastoma 12.4
12 neuroblastoma 1 10.8
13 causalgia 10.4 ENO2 NTRK1
14 spinal canal and spinal cord meningioma 10.4 CHGA ENO2
15 diffuse pulmonary fibrosis 10.4 CHGA ENO2
16 central nervous system benign neoplasm 10.4 ENO2 SYP
17 mixed cell type cancer 10.4 ENO2 SYP
18 adrenal rest tumor 10.4 ENO2 SYP
19 cystic teratoma 10.4 ENO2 SYP
20 optic nerve neoplasm 10.4 ENO2 SYP
21 medullomyoblastoma 10.4 ENO2 SYP
22 adult medulloblastoma 10.4 ENO2 SYP
23 pineal parenchymal tumor of intermediate differentiation 10.4 ENO2 SYP
24 basaloid squamous cell carcinoma 10.4 ENO2 SYP
25 pilomatrixoma 10.4 ENO2 S100B
26 brain injury 10.4 ENO2 S100B
27 traumatic brain injury 10.4 ENO2 S100B
28 spondylosis 10.4 ENO2 S100B
29 granular cell tumor 10.4 ENO2 S100B
30 intracranial primitive neuroectodermal tumor 10.4 CHGA ENO2
31 meningeal melanocytoma 10.4 ENO2 S100B
32 acute mountain sickness 10.4 ENO2 S100B
33 tubular adenocarcinoma 10.4 CHGA SYP
34 gastric tubular adenocarcinoma 10.4 CHGA SYP
35 binswanger's disease 10.4 CHGA SYP
36 carotid body cancer 10.4 ENO2 SYP
37 somatostatinoma 10.4 CHGA ENO2
38 malignant sertoli cell tumor 10.4 ENO2 SYP
39 lung oat cell carcinoma 10.3 CHGA ENO2
40 goblet cell carcinoid 10.3 CHGA ENO2
41 pancreatic somatostatinoma 10.3 ENO2 SYP
42 cutaneous ganglioneuroma 10.3 ENO2 SYP
43 extrahepatic bile duct adenocarcinoma 10.3 ENO2 SYP
44 papillary tumor of the pineal region 10.3 ENO2 SYP
45 ureter small cell carcinoma 10.3 CHGA SYP
46 sensory organ benign neoplasm 10.3 ENO2 SYP
47 ectopic cushing syndrome 10.3 S100B SYP
48 orbital cancer 10.3 ENO2 SYP
49 intracranial cysts 10.3 ENO2 S100B
50 middle ear adenoma 10.3 ENO2 SYP

Graphical network of the top 20 diseases related to Olfactory Neuroblastoma:



Diseases related to Olfactory Neuroblastoma

Symptoms & Phenotypes for Olfactory Neuroblastoma

GenomeRNAi Phenotypes related to Olfactory Neuroblastoma according to GeneCards Suite gene sharing:

27 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-111 9.6 SSTR2
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 9.6 NTRK1
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 9.6 SSTR2
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-20 9.6 NTRK1
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.6 SSTR2
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-203 9.6 EWSR1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 9.6 EWSR1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 9.6 CHGA EWSR1 NTRK1 SSTR2
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 9.6 SSTR2
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 9.6 NTRK1
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-61 9.6 CHGA
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 9.6 SSTR2
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 9.6 EWSR1
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 9.6 EWSR1
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-89 9.6 EWSR1
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 9.6 SSTR2

MGI Mouse Phenotypes related to Olfactory Neuroblastoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.7 ENO2 NGFR NTRK1 NTRK2 S100B SSTR2
2 nervous system MP:0003631 9.56 CHGA ENO2 NGFR NTRK1 NTRK2 PTPRC
3 normal MP:0002873 9.1 NGFR NTRK1 NTRK2 PTPRC S100B SYP

Drugs & Therapeutics for Olfactory Neuroblastoma

Drugs for Olfactory Neuroblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 153)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
3
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
4
Cevimeline Approved Phase 3 107233-08-9 25137844 83898
5
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
6
Histamine Approved, Investigational Phase 3 51-45-6 774
7
Doxepin Approved, Investigational Phase 3 1668-19-5 667468 667477
8
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
9
Promethazine Approved, Investigational Phase 3 60-87-7 4927
10
Docetaxel Approved, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124
11 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
12 Liver Extracts Phase 3,Phase 2,Phase 1,Early Phase 1
13 Cola Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
15 Anti-Infective Agents Phase 2, Phase 3,Phase 1
16 Narcotics Phase 3
17 Adjuvants, Anesthesia Phase 3
18 Analgesics Phase 3
19 Anesthetics, Intravenous Phase 3
20 Anesthetics, General Phase 3
21 Anesthetics Phase 3
22 Analgesics, Opioid Phase 3
23 Central Nervous System Depressants Phase 3
24 Peripheral Nervous System Agents Phase 3,Not Applicable
25 Hormones Phase 2, Phase 3,Phase 1
26 Steroid Synthesis Inhibitors Phase 2, Phase 3
27 Hormone Antagonists Phase 2, Phase 3,Phase 1
28 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3,Phase 1
29 Cytochrome P-450 CYP2C9 Inhibitors Phase 2, Phase 3
30 Antifungal Agents Phase 2, Phase 3,Phase 1
31 Cytochrome P-450 CYP2C19 Inhibitors Phase 2, Phase 3
32 Muscarinic Agonists Phase 3
33 Neurotransmitter Agents Phase 3,Not Applicable
34 Autonomic Agents Phase 3,Not Applicable
35 Cholinergic Agents Phase 3,Not Applicable
36 Contraceptives, Oral Phase 3
37 Appetite Stimulants Phase 3
38 Central Nervous System Stimulants Phase 3,Not Applicable
39 Contraceptive Agents Phase 3
40 Antineoplastic Agents, Hormonal Phase 3
41
Megestrol Phase 3 3562-63-8 3080587 19090
42 Histamine Antagonists Phase 3
43 Psychotropic Drugs Phase 3
44 Antidepressive Agents, Tricyclic Phase 3
45 Antidepressive Agents Phase 3
46
Histamine Phosphate Phase 3 51-74-1 65513
47 Hypnotics and Sedatives Phase 3
48 Antimitotic Agents Phase 3,Phase 2,Phase 1
49
Indinavir Approved Phase 2 150378-17-9 5362440
50
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622

Interventional clinical trials:

(show top 50) (show all 64)
# Name Status NCT ID Phase Drugs
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
3 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3 fluconazole
4 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
5 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3 megestrol acetate
6 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
7 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
8 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
9 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
10 Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
11 Chemotherapy in Treating Patients With Solid Tumors Completed NCT00003103 Phase 1, Phase 2 docetaxel
12 High-dose ICE With Amifostine Completed NCT00003657 Phase 2 Amifostine;Carboplatin;Etoposide;Ifosfamide
13 Docetaxel in Treating Patients With Solid Tumors Completed NCT00003565 Phase 2 docetaxel
14 Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer Completed NCT00448552 Phase 2 capecitabine;oxaliplatin
15 Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor Completed NCT00021047 Phase 1, Phase 2 capecitabine;carboplatin;epirubicin hydrochloride
16 Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
17 Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients With Central Nervous System Cancer Completed NCT00007982 Phase 2 carmustine;cisplatin;cyclophosphamide;etoposide;thiotepa
18 Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer Completed NCT00509665 Phase 2 doxorubicin hydrochloride;gemcitabine hydrochloride
19 Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer Completed NCT00021333 Phase 2 cisplatin;paclitaxel
20 A Clinical Trial of Endoscopic Surgery Followed by Chemotherapy and Proton Radiation for the Treatment of Tumors in the Sinus and Nasal Passages Recruiting NCT03274414 Phase 2 Cisplatin;cisplatin and etoposide
21 Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Inoperable Patients Active, not recruiting NCT02099188 Phase 2 Cisplatin;Docetaxel;5-fluorouracil;Etoposide;Adriamycin;Ifosfamide;Leucovorin
22 Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients Active, not recruiting NCT02099175 Phase 2 Cisplatin;Docetaxel;5-fluorouracil;Etoposide;Adriamycin;Ifosfamide;Leucovorin
23 18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy Active, not recruiting NCT01806675 Phase 1, Phase 2 fludeoxyglucose F 18;2-fluoropropionyl-labeled pegylated dimeric RGD peptide
24 Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer Completed NCT01637194 Phase 1 everolimus
25 Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer Completed NCT00470496 Phase 1 HPPH;photodynamic therapy
26 Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00023959 Phase 1 hydroxyurea;fluorouracil
27 Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors Completed NCT00089362 Phase 1 alvespimycin hydrochloride
28 Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Completed NCT00397384 Phase 1 cetuximab;erlotinib hydrochloride
29 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
30 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
31 Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors Completed NCT01172028 Phase 1 Taxotere (Docetaxel);Alimta (Pemetrexed)
32 Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors Completed NCT00006036 Phase 1 cisplatin;lurtotecan liposome
33 Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function Completed NCT00002901 Phase 1 docetaxel
34 Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer Completed NCT00045006 Phase 1 vorinostat
35 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1 entinostat
36 Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer Completed NCT00019110 Phase 1
37 Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors Completed NCT00010023 Phase 1 capecitabine;cisplatin
38 Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer Completed NCT00004065 Phase 1 tanespimycin
39 NGR-TNF in Treating Patients With Advanced Solid Tumors Completed NCT00098943 Phase 1
40 Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Completed NCT00049296 Phase 1 docetaxel;thalidomide
41 Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors Completed NCT00014456 Phase 1 docetaxel;gemcitabine hydrochloride
42 SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck Completed NCT00005647 Phase 1 paclitaxel;semaxanib
43 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
44 Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin Terminated NCT00023790 Phase 1 silicon phthalocyanine 4
45 S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors Withdrawn NCT00937417 Phase 1 docetaxel;vandetanib
46 Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer Completed NCT00068497 Not Applicable gefitinib
47 Customized Headrest or Standard Headrest in Holding Patients Still While Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00973947 Not Applicable
48 Collecting and Storing Tissue Samples From Patients With Head and Neck Cancer Completed NCT00898300
49 Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer Completed NCT00897793
50 Immunoreactivity to Cetuximab in Cancer Patients Completed NCT00896896

Search NIH Clinical Center for Olfactory Neuroblastoma

Cochrane evidence based reviews: esthesioneuroblastoma, olfactory

Genetic Tests for Olfactory Neuroblastoma

Anatomical Context for Olfactory Neuroblastoma

MalaCards organs/tissues related to Olfactory Neuroblastoma:

42
Bone, Brain, Eye, Kidney, Thyroid, Liver, Skin

Publications for Olfactory Neuroblastoma

Articles related to Olfactory Neuroblastoma:

(show top 50) (show all 681)
# Title Authors Year
1
Hyperostotic esthesioneuroblastoma as a fibrous dysplasia mimicker. ( 29789119 )
2019
2
Patterns of failures after surgical resection in olfactory neuroblastoma. ( 30506150 )
2019
3
Adrenocorticotropic Hormone-Dependent Cushing Syndrome Caused by an Olfactory Neuroblastoma. ( 30728732 )
2019
4
Comparing Kadish, TNM, and the modified Dulguerov staging systems for esthesioneuroblastoma. ( 30466166 )
2019
5
Utility of adjuvant chemotherapy in patients receiving surgery and adjuvant radiotherapy for primary treatment of esthesioneuroblastoma. ( 30536472 )
2019
6
Diffusion weighted imaging of esthesioneuroblastoma: Differentiation from other sinonasal masses. ( 30848032 )
2019
7
Esthesioneuroblastoma: A Comprehensive review of Diagnosis, Management and current Treatment options. ( 30862589 )
2019
8
Correlating the treatment outcome with tumor staging, grading, and various treatment modalities in patients with esthesioneuroblastoma. ( 31069195 )
2019
9
Paraneoplastic limbic encephalitis associated with mixed olfactory neuroblastoma and craniopharyngioma: A case report and literature review. ( 29901583 )
2018
10
Paraneoplastic limbic encephalitis associated with mixed olfactory neuroblastoma and craniopharyngioma: A case report and literature review: Erratum. ( 29995829 )
2018
11
Esthesioneuroblastoma: An Unusual Presentation with Intractable Headache. ( 30723652 )
2018
12
Olfactory Neuroblastoma: A Rare Cause of External Ophthalmoplegia, Proptosis and Compressive Optic Neuropathy. ( 29755824 )
2018
13
Pulmonary nocardiosis mimicking small cell lung cancer in ectopic ACTH syndrome associated with transformation of olfactory neuroblastoma: a case report. ( 30134888 )
2018
14
Olfactory neuroblastoma: a single-center experience. ( 28540633 )
2018
15
Volumetric analysis of olfactory neuroblastoma skull base laterality and implications on neck disease. ( 28833165 )
2018
16
Importance of neoadjuvant chemotherapy in olfactory neuroblastoma treatment: Series report and literature review. ( 29061289 )
2018
17
Early Stage olfactory neuroblastoma and the impact of resecting dura and olfactory bulb. ( 29226334 )
2018
18
Ectopic Cushing's syndrome secondary to olfactory neuroblastoma. ( 29340776 )
2018
19
Olfactory Neuroblastoma. ( 29411144 )
2018
20
Sinonasal Neuroendocrine Neoplasms: Current Challenges and Advances in Diagnosis and Treatment, with a Focus on Olfactory Neuroblastoma. ( 29427030 )
2018
21
An unusual manifestation of olfactory neuroblastoma. ( 29535093 )
2018
22
DNA methylation-based reclassification of olfactory neuroblastoma. ( 29730775 )
2018
23
Surgical Treatment of Olfactory Neuroblastoma: Major Complication Rates, Progression Free and Overall Survival. ( 29868319 )
2018
24
Age distribution and age-related outcomes of olfactory neuroblastoma: a population-based analysis. ( 29881306 )
2018
25
Clinical features and the molecular biomarkers of olfactory neuroblastoma. ( 29921494 )
2018
26
Intracranial immature teratoma invading the nasal cavity mimicking olfactory neuroblastoma: A case report. ( 29995824 )
2018
27
Non-contiguous Meningeal Recurrence of Olfactory Neuroblastoma: A Case Report and Literature Review. ( 30023143 )
2018
28
Endonasal endoscopic resection of olfactory neuroblastoma: an 11-year experience. ( 30074458 )
2018
29
Correction to: DNA methylation-based reclassification of olfactory neuroblastoma. ( 30094618 )
2018
30
Patient characteristics of olfactory neuroblastoma: experience from a tertiary cancer centre 2000-2016 covering Eastern Denmark. ( 30168622 )
2018
31
Olfactory neuroblastoma treated with minimally invasive surgery and adjuvant radiotherapy: a case report and review of the literature. ( 30363190 )
2018
32
Ectopic adrenocorticotropic hormone syndrome associated with olfactory neuroblastoma: acquirement of adrenocorticotropic hormone expression during disease course as shown by serial immunohistochemistry examinations. ( 30392451 )
2018
33
Genomic analysis identifies frequent deletions of Dystrophin in olfactory neuroblastoma. ( 30575736 )
2018
34
A Case of Cushing's Syndrome due to Ectopic Adrenocorticotropic Hormone Secretion from Esthesioneuroblastoma with Long Term Follow-Up after Resection. ( 29515922 )
2018
35
Esthesioneuroblastoma: A Patterns-of-Care and Outcomes Analysis of the National Cancer Database. ( 29481629 )
2018
36
Neuroradiological and Neuropathological Changes After 177Lu-Octreotate Peptide Receptor Radionuclide Therapy of Refractory Esthesioneuroblastoma. ( 29554305 )
2018
37
Bilateral Adrenal Hyperplasia Due to Adrenocorticotropic Hormone-Secreting Esthesioneuroblastoma on FDG PET and 111In-Pentetreotide Scintigraphy. ( 29659387 )
2018
38
Esthesioneuroblastoma with distant metastases: Systematic review & meta-analysis. ( 29756250 )
2018
39
Changing Trends in the Management of Esthesioneuroblastoma: Irish and International Perspectives. ( 29765824 )
2018
40
An Unusual Presentation of Esthesioneuroblastoma in a Young Pregnant Female. ( 29765954 )
2018
41
Esthesioneuroblastoma metastatic to the breast. ( 29781189 )
2018
42
Esthesioneuroblastoma and Olfactory Preservation: Is it Reasonable to Attempt Smell Preservation? ( 29868325 )
2018
43
Esthesioneuroblastoma with widespread distant metastasis: Case report and literature review. ( 29940688 )
2018
44
Dural Invasion Predicts the Laterality and Development of Neck Metastases in Esthesioneuroblastoma. ( 30210978 )
2018
45
Endoscopic management of Esthesioneuroblastoma: Our experience and review of the literature. ( 30340976 )
2018
46
Advanced Radiation Techniques in the Treatment of Esthesioneuroblastoma: A 7-Year Single-Institution's Clinical Experience. ( 30463343 )
2018
47
Endoscopic endonasal management of esthesioneuroblastoma: A retrospective multicenter study. ( 28595773 )
2018
48
Intranasal Esthesioneuroblastoma: CT Patterns Aid in Preventing Routine Nasal Polypectomy. ( 29217745 )
2018
49
Endoscopic endonasal resection of sinonasal/anterior skull base malignancy (Kadish C esthesioneuroblastoma). ( 29277853 )
2018
50
Exploration of the optimal treatment regimes for Esthesioneuroblastoma: a single center experience in China. ( 29290783 )
2018

Variations for Olfactory Neuroblastoma

Copy number variations for Olfactory Neuroblastoma from CNVD:

7 (show all 31)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 31526 1 28000000 30200000 Gain Olfactory neuroblastoma
2 34250 1 5400000 7200000 Gain Olfactory neuroblastoma
3 41470 10 18700000 22600000 Gain Olfactory neuroblastoma
4 63735 12 120700000 125900000 Gain Olfactory neuroblastoma
5 74688 13 110300000 115169878 Gain CUL4A Olfactory neuroblastoma
6 74689 13 110300000 115169878 Gain TFDP1 Olfactory neuroblastoma
7 75167 13 17900000 115169878 Gain Olfactory neuroblastoma
8 77744 13 47300000 55300000 Gain Olfactory neuroblastoma
9 79881 13 79000000 87700000 Gain Olfactory neuroblastoma
10 91527 15 31200000 33600000 Gain Olfactory neuroblastoma
11 101890 16 47000000 52600000 Gain Olfactory neuroblastoma
12 150427 20 1 27500000 Gain Olfactory neuroblastoma
13 151980 20 27500000 63025520 Gain Olfactory neuroblastoma
14 152120 20 29400000 37600000 Gain Olfactory neuroblastoma
15 154980 20 5100000 12100000 Gain Olfactory neuroblastoma
16 155529 20 56500000 63025520 Gain BRK Olfactory neuroblastoma
17 159453 21 42600000 48129895 Gain Olfactory neuroblastoma
18 163221 22 25900000 29600000 Gain Olfactory neuroblastoma
19 179990 4 1 6000000 Gain Olfactory neuroblastoma
20 181394 4 120800000 191154276 Gain Olfactory neuroblastoma
21 184608 4 17800000 48200000 Gain Olfactory neuroblastoma
22 187607 4 52700000 59500000 Gain Olfactory neuroblastoma
23 190046 4 82400000 93700000 Gain Olfactory neuroblastoma
24 196156 5 159900000 168500000 Gain Olfactory neuroblastoma
25 196538 5 168500000 180915260 Gain Olfactory neuroblastoma
26 213457 6 46200000 51800000 Gain Olfactory neuroblastoma
27 227898 7 72200000 77500000 Gain FZD9 Olfactory neuroblastoma
28 227899 7 72200000 77500000 Gain LIMK1 Olfactory neuroblastoma
29 228591 7 77500000 86400000 Gain Olfactory neuroblastoma
30 251884 9 33200000 36300000 Gain Olfactory neuroblastoma
31 257109 X 1 155270560 Gain Olfactory neuroblastoma

Expression for Olfactory Neuroblastoma

Search GEO for disease gene expression data for Olfactory Neuroblastoma.

Pathways for Olfactory Neuroblastoma

GO Terms for Olfactory Neuroblastoma

Cellular components related to Olfactory Neuroblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.02 NGFR NTRK1 NTRK2 PTPRC SSTR2

Biological processes related to Olfactory Neuroblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.63 NTRK1 NTRK2 PTPRC
2 cellular response to nerve growth factor stimulus GO:1990090 9.43 NTRK1 NTRK2
3 positive regulation of axonogenesis GO:0050772 9.4 NGFR NTRK2
4 cellular response to amyloid-beta GO:1904646 9.37 NGFR NTRK1
5 regulation of neuronal synaptic plasticity GO:0048168 9.32 S100B SYP
6 mechanoreceptor differentiation GO:0042490 9.26 NTRK1 NTRK2
7 neurotrophin signaling pathway GO:0038179 9.16 NTRK1 NTRK2
8 positive regulation of MAPK cascade GO:0043410 9.13 NTRK1 NTRK2 PTPRC
9 neurotrophin TRK receptor signaling pathway GO:0048011 8.8 NGFR NTRK1 NTRK2

Molecular functions related to Olfactory Neuroblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nerve growth factor binding GO:0048406 9.16 NGFR NTRK1
2 transmembrane signaling receptor activity GO:0004888 8.96 NGFR
3 neurotrophin receptor activity GO:0005030 8.96 NTRK1 NTRK2
4 neurotrophin binding GO:0043121 8.8 NGFR NTRK1 NTRK2

Sources for Olfactory Neuroblastoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....